Articles with public access mandates - Björn Schumacher - National Institute for Health Research, UKLearn more
NoteFor this mandate, articles should be available from specific locations.
OverallDFGEuropean CommissionNIHBMBFMRCWellcomeNSFCHelmholtzSwedish Research CouncilBHFCancer Research UKNIHRGovernment of SpainHealth Data Research, UKDOEDoDVAHHMIVolkswagen FoundationBanking Foundation "la Caixa"BBSRCRCNANRKNAWGovernment of ItalyMichael J Fox FoundationUK Research & InnovationGovernment of Argentina
Not available based on mandate: 1
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
PK Judge, N Staplin, KJ Mayne, C Wanner, JB Green, SJ Hauske, ...
The Lancet Diabetes & Endocrinology 12 (1), 51-60, 2024
Available based on mandate: 1
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
N Staplin, R Haynes, PK Judge, C Wanner, JB Green, J Emberson, ...
The Lancet Diabetes & Endocrinology 12 (1), 39-50, 2024
Publication and funding information is determined automatically by a computer program